{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:29:14Z","timestamp":1792290554134,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ekir.2020.09.046","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T12:36:12Z","timestamp":1602506172000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With\u00a0Refractory Nephrotic Syndrome"],"prefix":"10.1016","volume":"6","author":[{"given":"Elias","family":"Jatem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Torres-Bondia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2020.09.046_bib1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2020.09.046_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/kisup.2012.15","article-title":"Chapter 2: General principles in the management of glomerular disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2020.09.046_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0272-6386(12)70179-8","article-title":"The nephrotic syndrome, lipids, and risk factors for cardiovascular disease","volume":"22","author":"Radhakrishnan","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.09.046_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","article-title":"The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia","volume":"134","author":"Haas","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2020.09.046_bib5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","article-title":"Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome","volume":"29","author":"Liu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.09.046_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.ajkd.2013.10.042","article-title":"Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study","volume":"63","author":"Jin","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.09.046_bib7","doi-asserted-by":"crossref","unstructured":"Kohli M, Patel K, MacMahon Z, et\u00a0al. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres [e-pub ahead of print]. Int J Clin Pract. https:\/\/doi.org\/10.1111\/ijcp.13032. Accessed October 17,\u00a02020.","DOI":"10.1111\/ijcp.13032"},{"key":"10.1016\/j.ekir.2020.09.046_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12882-017-0644-0","article-title":"Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report","volume":"18","author":"Awanami","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2020.09.046_bib10","first-page":"139","article-title":"KDIGO clinical practice guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ekir.2020.09.046_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1016\/j.ekir.2020.09.046_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2020.09.046_bib13","first-page":"CD005425","article-title":"Lipid-lowering agents for nephrotic syndrome","volume":"10","author":"Kong","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2020.09.046_bib14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2146\/ajhp060241","article-title":"Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome","volume":"64","author":"Jose","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ekir.2020.09.046_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy-a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.09.046_bib16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2020.09.046_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","article-title":"Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS study","volume":"19","author":"Muso","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2020.09.046_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000437338","article-title":"A\u00a0prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome","volume":"5","author":"Muso","year":"2015","journal-title":"Nephron Extra"},{"key":"10.1016\/j.ekir.2020.09.046_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J\u00a0Lipid Res"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920316363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920316363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:35:02Z","timestamp":1762832102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024920316363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2468024920316363"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2020.09.046","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With\u00a0Refractory Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2020.09.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}